Press Releases

Latest

LumaCyte Launches New Compact Radiance® Instrument for Advanced Therapy Biomanufacturing & QC Environments

October 2023

LumaCyte, a leading innovator in advanced single cell analysis technology and instrumentation, is proud to announce the launch of their newly redesigned flagship Radiance® instrument to meet growing demand for Laser Force Cytology™ (LFC) precision analytics in space-constrained biomanufacturing facilities. The half-sized compact design is new, occupying only 16 inches of bench space, but the underlying technology remains unchanged. Utilizing LFC, LumaCyte’s Radiance® platform instrument provides real-time, label-free, quantitative cell characterization analytics for better manufacturing controls.

LumaCyte Fueled for Growth, Names Top Life Sciences Industry Executives to Board

March 2022

LumaCyte announces the successful completion of A round financing that will allow the company to accelerate global growth, in addition to announcing the appointmentment of two industry executives, Paul M. Meister, and Peter L. Buzy, to its Board of Directors.

LumaCyte Appoints Vaccine Manufacturing Expert to Scientific Advisory Board

April 2021

LumaCyte announces the addition of Jim Robinson to its Scientific Advisory Board (SAB). Jim brings more than 35 years of CMC vaccine manufacturing experience to the LumaCyte SAB, holding previous executive level positions at Merck, Sanofi Pasteur and Novavax.

LumaCyte’s Laser Force Cytology Accelerating Gene Therapy Production

January 2020

LumaCyte recently collaborated with global cell and gene therapy leader, Catalent, where their joint teams uncovered valuable new capabilities in the monitoring of adeno-associated virus (AAV) production and infectivity, foundational precursors in the production of gene therapy products.

LumaCyte Expands into Europe Tackling Expansive Vaccine and Cell and Gene Therapy Markets

February 2020

LumaCyte launches European subsidiary, LumaCyte, B.V., in the Netherlands to serve as its hub for instrument sales and service in EMEA. Having resources close to our customers is critical for maintaining outstanding customer service and support.

LumaCyte joins The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

September 2017

LumaCyte joins The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a Manufacturing USA institute sponsored by the National Institute of Standards and Technology (NIST).